In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RWJ-270201

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 3, 2001, Pages 749-757

  Sidwell, R W ^a   Smee, D F ^a   Huffman, J H ^a   Barnard, D L ^a   Bailey, K W ^a   Morrey, J D ^a   Babu, Y S ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPENTANE DERIVATIVE; OSELTAMIVIR; PERAMIVIR; RIBAVIRIN; SIALIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTERIAL OXYGEN TENSION; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; INFLUENZA; INFLUENZA VIRUS; LUNG DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

ACETAMIDES; ANIMALS; ANTIVIRAL AGENTS; CYCLOPENTANES; DISEASE MODELS, ANIMAL; FEMALE; GUANIDINES; INFLUENZA A VIRUS; INFLUENZA B VIRUS; LUNG; MICE; MICE, INBRED C57BL; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; RESPIRATORY FUNCTION TESTS; RIBAVIRIN; VIRUS REPLICATION;

EID: 0035118548     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.3.749-757.2001     Document Type: Article

References (22)

1. BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design
2. Update: Influenza activity - United States, 1999-2000 season
3. Penetration of GS4071, a novel neuraminidase inhibitor, into rat broncho-alveolar lining fluid following oral administration of the prodrug GS4104
4. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza
5. Efficacy of intranasal GG167 in experimental human influenza A and B virus infection
6. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections
7. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza
8. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment
9. Identification of GS4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS4071
10. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection
11. Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections
12. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections
13. Zanamivir in the prevention of influenza among healthy adults: A randomized controlled trial
14. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: Pooled efficacy studies
15. Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial
16. Determination of antiviral activity
17. Broad-spectrum antiviral activity of virazole: 1-β-D-ribofuranosyl-1.2,4-triazole-3-carboxamide
18. Effect of selenazofurin on influenza A and B virus infections in mice
19. Utilization of pulse oximetery for the study of the inhibitory effects of antiviral agents on influenza virus in mice
20. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor
21. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities
22. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial